Mount Sinai Health System Launches Elementa Labs, A Virtual Incubator Program
Elementa Labs will connect health care startup companies with Mount Sinai’s vast network of research and clinical experts to advance groundbreaking health care innovations. Mount Sinai Innovation Partners (MSIP), the commercialization engine of the Mount Sinai Health System (Mount Sinai) in New …
Kantaro’s Semi-Quantitative Antibody Test Kit Receives Health Canada Authorization Under the COVID-19 Interim Order
-COVID-SeroKlir detects both the presence and precise level of neutralizing IgG antibodies with 98.8% sensitivity and 99.6% specificity -Available immediately and can be used in Canadian laboratories without proprietary equipment Kantaro Biosciences, LLC (Kantaro), a joint venture between the Mount Sinai Health …
UK Vivan Therapeutics Secures Expanded Drug Discovery & Development Platform From Mount Sinai Health System in New York
My Personal Therapeutics Ltd. (trading as Vivan Therapeutics), a UK-based company, announces an expansion of its licensed technology rights from Mount Sinai Health System. Scientists at the Icahn School of Medicine at Mount Sinai Center for Personalized Cancer Therapeutics (CPCT) in New …
Kantaro’s COVID-SeroKlir Antibody Test Named as a Finalist for Fast Company’s 2021 World Changing Ideas Awards
Kantaro Biosciences, LLC, a joint venture between the Mount Sinai Health System and RenalytixAI (LSE: RENX / NASDAQ: RNLX), announced today that COVID-SeroKlir, its semi-quantitative SARS-CoV-2 IgG antibody test, was named as a finalist in the Pandemic Response category of the 2021 …
Trellus Health Announces Experienced Leaders to Drive Next Phase of Growth
Industry veterans from Teladoc Health, Talkspace, Harwood Capital and Polar Capital join executive team and board of directors Trellus Health, a leading resilience-driven connected health solution for chronic conditions, announced several important additions to its executive team and board of directors. The …
Mount Sinai Venture Named to Fast Company’s Annual List of the World’s Most Innovative Companies for 2021
Kantaro Biosciences among top-ranked in the Joint Venture category Mount Sinai Health System announced today that Kantaro Biosciences, LLC, a joint venture with RenalytixAI, has been named to Fast Company’s prestigious annual list of the “World’s Most Innovative Companies” for 2021 and …
Vaxalto Biotherapeutics and Mount Sinai Enter into Exclusive License Agreement for the Development and Commercialization of Novel Immunotherapeutic Oncolytic Viruses for Treatment of Cancer
Vaxalto Biotherapeutics, Inc. (www.vaxalto.com), a pre-clinical stage biotechnology company focused on developing and commercializing novel engineered immunotherapeutic oncolytic viruses, and Mount Sinai Innovation Partners (MSIP), part of the Icahn School of Medicine at Mount Sinai, have partnered to develop novel cancer immunotherapies. Mount Sinai has …
FDA Adds Kantaro’s Semi-Quantitative COVID-19 Antibody Test to Revised Emergency Use Authorization for Convalescent Plasma
COVID-SeroKlir is a high-performance test that detects the presence and precise level of SARS-CoV-2 IgG antibodies NEW YORK, Feb. 10, 2021 — Kantaro Biosciences, LLC, a joint venture between the Mount Sinai Health System and RenalytixAI (LSE:RENX /NASDAQ: RNLX), and manufacturing partner …
Kantaro and Atrys Health Partnership Expand Global Footprint of Quantitative COVID-19 Antibody Tests in Europe and South America
Kantaro’s COVID-SeroKlir and COVID-SeroIndex are high-performing tests that detect the presence and precise level of neutralizing antibodies¹ First and only quantitative COVID-19 antibody tests that do not require proprietary equipment NEW YORK, Feb. 8, 2021 — Kantaro Biosciences, LLC, a joint venture …
Kantaro Receives FDA Emergency Use Authorization for Semi-Quantitative COVID-19 Antibody Test Kit that Detects the Presence and Level of SARS-CoV-2 IgG Antibodies
COVID-SeroKlir is a high-performance semi-quantitative antibody test kit based on Mount Sinai technology, with a broad range of applications in the fight against COVID-19 The Kantaro test is being manufactured at scale and immediately available in the U.S. NEW YORK, Nov. 25, 2020 /PRNewswire/ …